April 2020 - Global Life Science Business Partnering - News & Updates

Highlights of April 2020

  1. Cellix Bio Pharma Initiates Acquisition of Avaca Pharma.
  2. Biocon-Mylan deal results in launch of  Fulphila, a biosimilar of pegfilgrastim, in Australia to treat cancer patients.
  3. Indian Immunologicals, Griffith University partner to develop vaccine for Covid-19.
  4. Supernus links up with Navitor on potential US$475 Million deal.
  5. Samsung scores US$362 Million deal to help Vir scale up COVID-19 antibody production.
  6. Arrakis Therapeutics inks US$190 Million upfront RNA drug deal with pharma giant.
  7. GSK partners with Arthritis Foundation as it preps Voltaren for OTC switch.
  8. J&J inks 2nd manufacturing deal to boost capacity for COVID-19 vaccine.
  9. Dynavax, Sinovac the latest to ally on a COVID-19 vaccine.
  10. Startup Biofourmis moves into oncology with Gaido Health acquisition.
  11. LFB inks deal with Xenothera for XAB-19, for treatment of coronavirus infections.
  12. MEI Pharma and Kyowa Kirin expand collaboration for the treatment of B-cell malignancies.
  13. EpiVax partners with GVF to make COVID-19 vaccine license-free to developing countries.
  14. Amgen and Adaptive Biotechnologies announce strategic partnership to develop fully human neutralizing antibodies targeting SARS-CoV-2 to potentially prevent or treat COVID-19.
  15. Kite Pharma Licenses Teneobio’s Antibody Platform to Fight Multiple Myeloma.

Highlights at Aagami

  • BIO Digital 2020 – Partnering Now Open! For E – Meeting please contact: Godwyn Francis – VP, Aagami, Inc. at Godwyn@aagami.com or send us a meeting request on the BIO Digital 2020 Platform.
  • Aagami received an assignment from Israel based biotech client to represent them in multiple virtual partnering events.

Some of the partnering opportunities available at Aagami are:

  1. Available for Acquisition: PharmaPEG® technology & associated assets to make Next-Generation Bio-Therapeutics.
  2. Seeking US$1.5M for Drug-device to delay the progression of Parkinson’s disease (PD), prevent Asian Flush and Hangover.
  3. Available for Licensing: Selection Technology using Bacteriocin-Immunity for Improved Microbial (E. coli.) Fermentation.
  4. Seeking US$1M for expansion of a Cancer healthcare and data science company.
×
Twitter